<DOC>
	<DOC>NCT00361569</DOC>
	<brief_summary>This is a four-arm, randomized, double-blind, parallel group, placebo-controlled study to compare the effects of two doses of DR-2041(Synthetic Conjugated Estrogens, A) Vaginal Cream on vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy</brief_title>
	<detailed_description>The study will include a screening period up to 4 weeks and a 12- week treatment period. The overall study duration for participants will be approximately 16 weeks. Study participants will undergo physical and gynecological exams, and blood tests for clinical laboratory assessments. All patients with a uterus will undergo transvaginal ultrasound.</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens, conjugated synthetic A</mesh_term>
	<criteria>Naturally or surgically menopausal Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse) Known sensitivity or contraindication to estrogens or progestins History or current diagnosis endometrial hyperplasia Recent history of vaginal bleeding of unknown cause Recent history or diagnosis of endometriosis Any contraindication to estrogen therapy</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>vaginal atrophy</keyword>
	<keyword>vaginal dryness</keyword>
	<keyword>vaginal itching</keyword>
	<keyword>vaginal pain</keyword>
</DOC>